DAXXIFY (daxibotulinumtoxinA) injection represents a novel approach to treating cervical dystonia in adults and addressing moderate to severe glabellar lines associated with muscle activity, offering potential relief and aesthetic enhancement for patients.
Powered by Revance's innovative Peptide Exchange Technology, DAXXIFY stands out for its unique formulation free of human serum albumin or animal-based components, potentially reducing the risk of adverse reactions and addressing safety concerns commonly associated with traditional botulinum toxin injections.
Revance Therapeutics, Inc.'s recent presentations at the American Academy of Neurology (AAN) conferen...